A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis

NCT ID: NCT00324142

Last Updated: 2012-08-02

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL

Brief Summary

This is a study of the drug tinidazole for women with recurrent bacterial vaginosis. Half of the participants will get the drug for 10 days, the other half will get the drug for 10 days and then twice a week for 12 weeks.

Detailed Description

This study will recruit 60 women with recurrent bacterial vaginosis. These women must have a current infection to be enrolled in the study and have had two other infections within the past 12 months. After initial screening to make sure that the vaginal symptoms are due to bacterial vaginosis and not the results of a different infection, all of the women will receive tinidazole (a drug that is similar to metronidazole) by mouth for 10 days. At the end of the 10 days, patients will be re-examined. Those women who are free of bacterial vaginosis will enter the second phase of the study, where half of the patients will continue to take tinidazole twice a week for twelve weeks and the other half will take no medication. During this time participants will be examined by the study doctor every 4 weeks to see how effective the treatment has been at preventing the recurrence of bacterial vaginosis. At the end of the 12 weeks, women who are still free of bacterial vaginosis will be seen for 3 more visits over 3 months.

Conditions

Recurrent Bacterial Vaginosis

Keywords

Bacterial vaginosis; Tinidazole; Vaginitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Oral tinidazole

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Current infection with bacterial vaginosis
• 2 previous episodes of bacterial vaginosis within the past 12 months
• Willing to use contraception
• Able to swallow pills
• Willing to refrain from douching or using vaginal products
• Willing to refrain from alcohol consumption 24 hours before and for 72 hours after taking study medication (tinidazole)

Exclusion Criteria

• Women with same sex partners
• Menstruating at initial exam
• Presence of yeast, a sexually transmitted disease, or other vaginal infection
• Purulent cervical discharge
• Use of any drug for bacterial vaginosis or yeast within the past 2 weeks prior to enrollment
• Pregnant or nursing
• Taking lithium
• Taking blood thinners (anticoagulation therapy)
• Use of any investigational drug within the previous 30 days
• Active HPV infection requiring treatment
• Use of drugs that suppress the immune system
• History of alcoholism
• Taking disulfiram

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Kaiser Permanente

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jennifer Gunter, MD

Role: PRINCIPAL_INVESTIGATOR

Kaiser Permamente

Locations

Kaiser Permanente

San Francisco, California, United States

Countries

United States

Other Identifiers

CN-06JGunt-01-B

Identifier Type: -

Identifier Source: org_study_id